Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends two drugs for ovarian cancer but rejects three

Paclitaxel and Caelyx given preliminary nod
NICE

NICE has recommended paclitaxel and Jansen-Cilag's Caleyx for the treatment of ovarian cancer in draft guidance.

Both paclitaxel and Caelyx (pegylated liposomal doxorubicin hydrochloride) are recommended as monotherapy and also in combination with platinum-based therapies.

But the cost-effectiveness body rejected GlaxoSmithKline's Hycamtin (topotecan), PharmaMar's Yondelis (trabectedin) and Lilly's Gemzar (gemcitabine) for treating the first recurrence of platinum-sensitive ovarian cancer.

Hycamtin was also provisionally not recommended for treating cancer that has returned within six months of treatments with a platinum-based regimen or cancer that does not respond to platinum treatment at all.

Meindert Boysen, NICE programme director of appraisals, said: “NICE makes difficult decisions to ensure that people using the NHS get access to the most cost-effectiveness treatments, and to help the NHS to share its resources fairly.

“This draft guidance recommends paclitaxel and pegylated liposomal doxorubicin hydrochloride for the treatment of ovarian cancer that has returned after previous treatment with platinum chemotherapy. 

“However the independent committee found that the evidence on the further three drugs indicated that they didn't provide enough extra health benefit for the cost to the NHS.”

Ovarian cancer is a common gynaecological cancer. The most common type of ovarian cancer arises from epithelial cells (the outside layer of cells) on the surface of the ovary, and can often spread from the ovary to any surface within the abdominal cavity including the fallopian tubes and peritoneal cavity.

Ovarian cancer predominantly occurs in older women, with over 80% of cases being diagnosed in women over 50 years. In 2010, around 7,000 new cases of ovarian cancer were diagnosed. 

Article by
Nikhil Patel

26th November 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics